Expert Opinion on P2Y12 Inhibitors Use in Management of Acute Coronary Syndromes: Focus on Ticagrelor
In conclusion, ticagrelor (180 mg, 90 mg, and 60 mg doses), a potent antiplatelet is expected to reshape the antiplatelet use in the management of ACS.PMID:34781659
Source: Journal of the Association of Physicians of India - Category: General Medicine Authors: Immaneni Sathyamurthy M S Hiremath Jitendra Pal Sawhney Subhash Chandra Hrudanand Mishra C K Ponde Shuvanan Ray Suhas Hardas Sunil Sathe P C Rath Bagirath R Girish B Navasundi Vilas Magarkar C N Makhale Suvro Banerjee P R Vaidyanathan Amal Kanti Sen Pande Source Type: research
More News: Bleeding | Chronic Kidney Disease | Clopidogrel | Diabetes | Endocrinology | General Medicine | India Health | Ischemic Stroke | Plavix | Stroke | Thrombosis | Urology & Nephrology